Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
  • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
  • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
  • B29B15/00—Pretreatment of the material to be shaped, not covered by groups B29B7/00 - B29B13/00
  • B29B15/08—Pretreatment of the material to be shaped, not covered by groups B29B7/00 - B29B13/00 of reinforcements or fillers
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
  • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
  • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
  • B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
  • B29C35/0266—Local curing
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
  • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
  • B29C70/00—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts
  • B29C70/04—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts comprising reinforcements only, e.g. self-reinforcing plastics
  • B29C70/06—Fibrous reinforcements only
  • B29C70/10—Fibrous reinforcements only characterised by the structure of fibrous reinforcements, e.g. hollow fibres
  • B29C70/16—Fibrous reinforcements only characterised by the structure of fibrous reinforcements, e.g. hollow fibres using fibres of substantial or continuous length
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
  • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
  • B29C70/00—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts
  • B29C70/04—Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts comprising reinforcements only, e.g. self-reinforcing plastics
  • B29C70/28—Shaping operations therefor
  • B29C70/30—Shaping by lay-up, i.e. applying fibres, tape or broadsheet on a mould, former or core; Shaping by spray-up, i.e. spraying of fibres on a mould, former or core
  • B29C70/38—Automated lay-up, e.g. using robots, laying filaments according to predetermined patterns
  • B29C70/382—Automated fiber placement [AFP]
  • B29C70/384—Fiber placement heads, e.g. component parts, details or accessories
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
  • G01N33/54306—Solid-phase reaction mechanisms
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
  • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
  • B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
  • B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
  • B29C2035/0211—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould resistance heating
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
  • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
  • B29C53/00—Shaping by bending, folding, twisting, straightening or flattening; Apparatus therefor
  • B29C53/56—Winding and joining, e.g. winding spirally
  • B29C53/58—Winding and joining, e.g. winding spirally helically
  • B29C53/581—Winding and joining, e.g. winding spirally helically using sheets or strips consisting principally of plastics material
  • B29C53/582—Winding and joining, e.g. winding spirally helically using sheets or strips consisting principally of plastics material comprising reinforcements, e.g. wires, threads
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
  • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
  • B29K2101/00—Use of unspecified macromolecular compounds as moulding material
  • B29K2101/10—Thermosetting resins
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
  • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
  • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
  • B29K2105/24—Condition, form or state of moulded material or of the material to be shaped crosslinked or vulcanised
  • B29K2105/243—Partially cured
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
  • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
  • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/26—Infectious diseases, e.g. generalised sepsis
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/50—Determining the risk of developing a disease

Definitions

• the present invention relates to the medical field in general, and in particular the field of resuscitation.
• the invention relates to a method for determining the susceptibility to nosocomial infections in a patient hospitalized in intensive care and / or having undergone an aggression, such as surgery, burn, trauma ..., generating a systemic inflammatory response or SIRS, especially in a patient in septic state, particularly severe, and preferably in a patient in septic shock.
• Nosocomial infections are an important public health problem. Inpatient patients often have, by their nature, diminished or impaired immune defenses, either because of pathologies that directly affect their immune skills, or because of their general condition. These patients, especially those who are malnourished or at extreme ages of life (elderly, infants) are especially susceptible to infections in general, and in particular to the occurrence of nosocomial infections.
• nosocomial infections The prevalence of nosocomial infections is significantly higher in intensive care units than in other hospital sectors.
• the significant incidence of nosocomial infections in this sector can be explained by the deleterious conjunction of several endogenous risk factors: patient exposure to invasive procedures (artificial ventilation, urinary catheterization, catheterization), patient severity (as well as associated comorbidities) and therapeutics (multiple transfusions, sedation).
• patient exposure to invasive procedures artificial ventilation, urinary catheterization, catheterization
• patient severity as well as associated comorbidities
• therapeutics multiple transfusions, sedation
• HLA-DR Human Leukocyte Antigen-DR
• mHLA-DR Human Leukocyte Antigen-DR
• flow cytometry requires special equipment (flow cytometer), which is not available on biological trays (used only in specialized hematology or immunology laboratories) and standardization of use is not established. Measurement of mHLA-DR can not be performed routinely.
• the present invention proposes to provide a new biomarker predictive of an increased risk of nosocomial infections in a patient, and in particular in a patient hospitalized in intensive care and / or having undergone an attack (surgery, burn, trauma ...) generating a systemic inflammatory response (SIRS), especially in a patient in seven state 'tque, particularly severe, and preferably in a patient with septic shock.
• SIRS systemic inflammatory response
• the study of the level of expression of this biomarker thus makes it possible to determine, easily and quickly, the susceptibility of a patient to nosocomial infections and to take the necessary preventive measures.
• the present invention therefore relates to a method for determining the susceptibility to nosocomial infections in a patient, comprising the following steps;
• the method for determining the susceptibility to nosocomial infections according to the invention is therefore a method implemented in vitro or ex vivo.
• SCD127 is the soluble or plasma form of CD127, an IL-7 receptor.
• the CD127 or IL-7 receptor alpha chain is a 75 kDa glycoprotein member of the hematopoietic growth factor receptor superfa thousand. It is expressed at the membrane level in combination with CD 132 (common y chain c) to form the I1L-7 receptor. This receptor plays an important role in differentiation, survival and lymphocyte proliferation.
• CD 127 consists of an extracellular portion of 219 amino acids (aa), a transmembrane portion of 25 aa and an intracytopiasmic portion of 195 aa.
• sCD127 a soluble / plasmatic form
• Nosocomial infection means any infection, mainly bacterial but also viral and fungal, that occurs in a health facility during or after management (diagnostic, therapeutic, palliative, preventive or educational), d. a patient, who was neither present nor incubating at the beginning of management. When the infectious state is not accurately known at the beginning of the treatment, a delay of at least 48 hours or a period longer than the incubation period is commonly accepted to define a nosocomial infection.
• systemic inflammatory response means a response associating at least two of the following criteria: Temperature> 38 ° C or ⁇ 36 ° C, Heart rate> 90 / minute, Respiratory rate > 20 / minute or paCO2 ⁇ 32 mmHg, Leucocytes> 12,000 / mm3 or ⁇ 4,000 / mm3 (Bone et al., Chest, 1992, 1644-1655.
• sCD127 means the soluble form or circulating form (also called plasma or serum form) of the IL-7 receptor, also called IL-7 receptor alpha chain or IL7R or IL7R-ALPHA or IL7RA or CDW127, and in particular as described by Goodwin et al, Cell, 1990, 23, 941-951 and assayed by Crawley et al, Journal of Immunology, 2010, 184, 4679-4687,
• the reference nucleic sequences for sCD127 according to the invention are preferably as follows: Ensembl: ENSG00000168685, HPRD-ID: 00893 Nucleotide sequence: N 002185,2, Vega genes: OTTHUMG00000090791.
• the reference protein sequences for SCD127 according to the invention are preferably the following: NPJD02176 XPJ542460; version: NP_002176.2 GI: 28610151.
• the sample to be tested in the context of the method of the invention is a biological sample from the patient in whom it is desired to determine the susceptibility to nosocomial infections.
• a biological sample is selected from those likely to contain the SCD127 marker.
• the present invention has a particularly preferred application in patients hospitalized in intensive care and / or having undergone an aggression, such as surgery, burn, trauma ..., generating a systemic inflammatory response or SIRS. Therefore, the biological sample used in the process of the invention is preferably from a patient hospitalized in intensive care and / or having undergone an aggression (surgery, burn, trauma, etc.) generating an answer.
• Systemic Inflammatory System SIRS
• the biological sample used in the context of the method of the invention is derived from a septic shock patient.
• the method of the invention makes it possible to determine the susceptibility of a patient to nosocomial infections, that is to say to conclude that there is an increased risk of developing a nosocomial infection or to an increased susceptibility to infections. nosocomial infections, when overexpression of SCD127 is demonstrated in the test sample with respect to a first reference value.
• overexpression is meant a statistically significant increase in the level of expression.
• the first reference value may correspond to the level of expression of sCD127 measured in a biological sample from a patient hospitalized in intensive care and / or having undergone an aggression, such as surgery, burn, trauma.
• generating a systemic inflammatory response or SIRS that is known to have failed to develop a nosocomial infection including a patient in a septic state who is known to have no nosocomial infection, and preferably a patient with septic shock who is known to have failed to develop a nosocomial infection.
• this measurement of the expression of sCD127 which constitutes the first reference value is preferably carried out in parallel, that is to say at the same time as the measurement of the expression of sCD127 which is made in the sample from the patient for which susceptibility to nosocomial infections is sought, although the baseline sample was taken prior to the sample to be tested.
• This first reference value may also correspond to an average value of the level of expression of sCD127 which is measured on a pool of samples from patients hospitalized in intensive care and / or having undergone an aggression, such as surgery, burn, trauma. .., generating a systemic inflammatory response (SIRS) that we know they do not have developed nosocomial infection, including patients in septic state who are known to have not developed a nosocomial infection, and preferably patients in septic shock who are known not to have developed infection nosocomial.
• SIRS systemic inflammatory response
• this measurement of the expression of sCD127 which constitutes the first reference value is preferably carried out prior to the measurement of the expression of SCD127 which is made in the sample from the patient in which it is sought to determine the Susceptibility to nosocomial infections, although the collection of reference samples intended to be “pooled” was carried out before that of the sample to be tested.
• the measurement of the expression of sCD127 in the test sample and, where appropriate, in the biological sample used to to obtain the first reference value, that is to say when the first reference value is obtained from a biological sample is carried out within 10 days or 10 days (D10) after the septic shock, preferably within 7 days or at 7 days (D7) after septic shock, more preferably within 4 days or at 4 days (D4) after septic shock, and in particular within 3 days or at 3 days (D3) after septic shock.
• the method of the invention makes it possible to determine the susceptibility of a patient to nosocomial infections, that is to say to conclude that there is an increased risk of developing a nosocomial infection or to an increased susceptibility to infections.
• Nosocomial infections when the expression of sCD127 which is measured in the test sample is not significantly reduced compared to a second reference value.
• it is concluded that there is an increased risk of developing a nosocomial infection if the expression of sCD127 which is measured in the test sample is not decreased by more than 25%, and in particular not decreased by more than 25%. 20%, compared to this second reference value.
• This second reference value may correspond to the level of expression of SCD127 measured in a biological sample from the same said patient during an earlier sample, that is to say in a biological sample that has been taken previously compared to the sample to be tested.
• prior or “prior” is meant earlier in time or prior to sampling of the test sample.
• the measurement of the expression of sCD127 in the sample to be tested is carried out approximately or at 10 days (D10) after septic shock, preferably about or 7 days (J7) after septic shock, more preferably about or 4 days (34) after septic shock.
• the previous sample may for example be made within 48 hours after the septic shock and at least 24 hours before that of the sample to be tested, and preferably the previous sample is taken within 48 hours after the septic shock and that of the test sample is made within 48 hours after the previous sample or 48 hours after the previous sample.
• the method of the invention may comprise the prior obtaining of the reference value, whether it is the first value of reference or the second reference value, at which the level of expression that will be detected in the test sample can be compared to conclude whether there is an increased risk of developing nosocomial infections in the patient from whom the sample originates to test.
• sample on which the method of the invention is implemented also called sample to be tested, can be of animal or human origin, and preferably human.
• the sample to be tested may be of different natures.
• this sample is a biological fluid, for example selected from blood, whole blood (as collected from the venous route, that is to say containing white and red cells, platelets and plasma), serum, plasma and bronchoalveolar lavage fluid.
• the test sample from said patient is a sample of plasma or serum.
• the samples from which the reference values can be determined may be of different natures and in particular of a biological nature as mentioned above. above concerning the sample to be tested (biological fluids).
• these biological samples are of the same nature as that of the biological sample to be tested or at least of a compatible nature to constitute a reference as to the detection and / or quantification of the expression of sCD127.
• these samples are preferably derived from persons having the same characteristics or a majority of common characteristics, in particular of the same sex and / or of a similar or identical age and / or of the same ethnic origin. , with those of the subject or patient at whom it is desired to determine susceptibility to nosocomial infections.
• the reference sample may also in this case be constituted by any sample, biological or non-biological, which has been previously calibrated to contain an average value of sCD127 which corresponds to the level that has been measured on a pool of biological samples from patients, hospitalized in intensive care and / or having undergone an aggression, such as surgery, burn, trauma ..., generating a systemic inflammatory response (SIRS) which one knows that they did not develop a nosocomial infection, in particular of patients in state are not known to have developed a nosocomial infection, and preferably patients with septic shock who are known to have failed to develop a nosocomial infection.
• the reference sample is derived from one or more patients in septic shock who are known to have (have) not developed a nosocomial infection.
• the reference sample is a biological sample from the same said patient, that is to say the patient in whom it is desired to determine the susceptibility to nosocomial infections and from which is derived the sample to be tested, but obtained from an earlier sample, that is to say from a biological sample that was taken earlier in time relative to the sample to be tested.
• the term "measure expression” is meant to be an in vitro or ex vivo measure.
• this term is intended to mean the detection and quantification of SCD127 at the protein level.
• any method of detection and / or quantification well known to those skilled in the art can be used for the implementation of the invention, whether in connection with the determination of the presence and / or measurement of the expression of the sCD127 protein.
• a method for measuring the expression of the sCD127 protein mention may be made especially of that described by Crawley et al, Journal of Immunology, 2010, 184, 4679-4687.
• the measurement of SCD127 expression level is performed using tools or reagents that are sCD127 specific and that allow, directly or indirectly, to determine its presence and / or to quantify its level. expression.
• tools or reagents those which are specific for the soluble form of the IL-7 receptor, that is to say which do not do not recognize CD127 which is the non-soluble cell / membrane form of this receptor.
• tools or reagents that recognize both the soluble form or sCD127 and the cellular form of the IL-7 or CD127 receptor can be used, as long as it is possible to distinguish these two forms by other means, such as for example the nature of the sample analyzed (for example, plasma or serum versus biological sample containing cells or whole blood).
• sCD127 When detection and / or quantification of sCD127 is performed at the protein level, standard techniques such as Western Blot, ELISA, RIA, IRMA, FIA, CLIA, ECL, flow cytometry or immunocytology can be used.
• the expression of sCD127 is measured at the protein level, and preferably using an ELISA technique.
• the level of expression of sCD127 is preferably measured using anti-sCD127 antibodies, monoclonal or polyclonal, and in particular anti-sCD127 monoclonal antibodies.
• anti-sCD127 antibodies monoclonal or polyclonal, and in particular anti-sCD127 monoclonal antibodies.
• the present invention also relates to the use of the measurement, in vitro or ex vivo, of the expression of sCD127 to determine the susceptibility of a patient to nosocomial infections.
• this use is particularly advantageous for determining the susceptibility to nosocomial infections of a patient hospitalized in intensive care and / or having undergone an aggression, such as surgery, burn, trauma ..., generating an inflammatory response.
• systemic or SIRS in particular of a patient in septic state, in particular severe, and preferably of a patient in septic shock.
• the use according to the invention makes it possible to determine the susceptibility to nosocomial infections of a patient in septic shock.
• the expression of sCD127 is preferably measured at the protein level, and in particular using an ELISA technique.
• the expression of sCD127 can be measured using anti-sCD127 antibodies, monoclonal or polyclonal, and preferably anti-sCD127 monoclonal antibodies.
• anti-sCD127 antibodies monoclonal or polyclonal, and preferably anti-sCD127 monoclonal antibodies.
• the antibodies mentioned above can also be used for this second aspect of the invention.
• the present invention also relates to a kit for measuring, in vitro or ex vivo, the expression of sCD127 in a biological sample, comprising:
• a positive control sample which is a sample calibrated to contain the amount of sCD127 which corresponds to the average amount measured in a pool of patient samples known to have developed a nosocomial infection
• a negative control sample which is a calibrated sample to contain the amount of sCD127 that corresponds to the average amount measured in a pool of patient samples that are known to have failed to develop a nosocomial infection.
• the kit according to the invention comprises specific tools or reagents for measuring the expression of SCD127 in said biological sample, and at least one control sample.
• the kit according to the invention makes it possible in particular to determine the susceptibility to nosocomial infections in a patient, and in particular in a patient in septic shock.
• the specific tools or reagents making it possible to measure the expression of sCD127 in a biological sample which are present in the kit of the invention make it possible to detect and / or quantify the expression of SCD127, whether at the protein level or at the level of sCD127 activity, and preferably at the protein level.
• the kit of the invention contains anti-sCD127 antibodies, monoclonal or polyclonal, and in particular monoclonal antibodies.
• Another positive control sample may also be a sample from a patient known to have developed a nosocomial infection.
• another negative control sample may also be a sample from a patient known to have no nosocomial infection.
• this type of control sample is preferably from one or more patient (s) hospitalized (s) in intensive care and / or having undergone an aggression, such as surgery, burn, trauma ..., generating a systemic inflammatory response (SIRS), including one or more patient (s) in septic status, and preferably one or more patient (s) in septic shock.
• SIRS systemic inflammatory response
• the kit may contain a negative control sample from one or more patient (s) hospitalized in intensive care and / or having undergone an aggression, such as surgery, burn, trauma ..., generating an answer Systemic Inflammatory Disease (SIRS), which is known to have failed to develop a nosocomial infection, particularly from one or more patients with septic shock who are known to be (s) has not developed a nosocomial infection.
• SIRS Systemic Inflammatory Disease
• the kit comprises both a positive control sample and a negative control sample, and in particular each selected from the calibrated samples as defined above.
• the invention also covers the use of a kit according to the invention for carrying out the method of the invention, and in particular for determining the susceptibility of a patient to nosocomial infections, preferably in a patient hospitalized in intensive care and / or or having undergone an aggression, such as surgery, burn, trauma ..., generating a systemic inflammatory response (SIRS), in particular in a patient in septic state, particularly severe, and preferably a patient in septic shock.
• SIRS systemic inflammatory response
• the use of the kit according to the invention makes it possible to determine the susceptibility to nosocomial infections in a patient in septic shock.
• FIG. 1 represents the concentration of plasma IL-7 in 35 patients in septic shock on days 1-2 (1-2) and 3-4 (3-4) and 30 healthy subjects "HV" (A) and the comparing these results by "NS" or “S” patient groups ( Figure 1B) and "NI” or “No NI” patient groups ( Figure 1C).
• FIG. 2 represents the expression of CD127 on CD4 + T cells (FIG. 2A) and on CD8 + T cells (FIG. 2B) in 35 septic shock patients on days 1-2 and 3-5 and 30 healthy subjects. " H V ".
• FIG. 3 represents the concentration of plasma SCD127 in 35 septic shock patients at days 1-2 and 3-4 and 30 healthy subjects (FIG. 3A) and the comparison of these results according to the groups of patients “NS" or “S” ( Figure 3B) and patient groups “NI” or “No NI” ( Figure 3C).
• FIG. 4 represents the expression of the HLA-DR marker in 35 septic shock patients on days 1-2 and 3-4 and 30 healthy subjects according to the "NI" or "No NI” patient groups.
• the plasma IL-7 concentration was measured using a kit using the LU INEX TM technique marketed by Bio-Rad (Bio-Plex Pro Cytokine, Chemokine and Growth Factor Assays: BioPlex Pro Reagent kit, Bio-Rad # 171-304070 and SinglePlex IL-7) following the instructions of the supplier.
• a "coating" buffer was prepared to contain 0.8 g Na 2 CO 3 , 1.4 g NaHCO 3 , 0.1 g NaN 3 in 500 ml of water (pH 9.6).
• Nonspecific binding was blocked with 150 ⁇ l blocking buffer per well (10% fetal bovine serum (FBS) / PBS-0.05% Tween 20 ), and then the plate was incubated for 1 hr. 37 ° C,
• sample or control solution of CD127 Fc chimera reconstituted extemporanérnent and aliquoté at concentrations of 60ng / m! iOng / m! were added to each well, and then the plate was incubated for 1h at 37 ° C
• streptavidin-HRP 8 ⁇ l / ml
• the contents of the wells were aspirated and the wells were washed 3 times with at least 300 ⁇ l of 0.05% PBS-Tween2O Wash Buffer. All the liquid was carefully removed with each wash. After the last wash, the plate was inverted on paper towels to remove all traces of buffer. At this washing step, the wells were soaked with the wash buffer 1 to 2 min before aspiration.
• the two bottles of the TMB (3,3 ', 5,5'-tetramethylbenzidine, bioMérieux # XX7LF1UC) color substrate solution were mixed volume-to-volume. 100 ⁇ l of this substrate solution was placed in each well. The plate was then covered to be incubated for 30 min at room temperature. Finally, the reading of the plate was carried out by measuring the absorbance at 450 nm.
• the measurement was carried out by the flow cytometry technique, using a direct labeling in whole blood taken on EDTA.
• the red blood cells were then removed: lysis by adding 1 ml of lysis solution (sold by the company Becton Dickinson under the reference 349202) diluted (1/10) (15 minutes at room temperature and in the dark).
• the cells were then analyzed on a flow cytometer (FC500 - Beckman Coulter).
• results are expressed in% of positive cells, the threshold of positivity being defined thanks to an isotypic control (Mouse IgG2a PE Becton Dickinson - Ref .: 349053).
• Various parameters or markers were measured such as plasma IL-7 and sCD127 concentrations, and CD127 expression on CD4 + T cells, and HLA-DR expression on monocytes.
• NS plasma IL-7 and sCD127 concentrations
• CD127 expression on CD4 + T cells CD4 + T cells
• HLA-DR expression on monocytes HLA-DR expression on monocytes.
• IL-7 receptor (CD127) cell expression is conserved after septic shock ( Figure 2A and 2B), and without any difference between surviving "S” patients or non-survivors "NS” or patients who have developed nosocomial infections "NI” or not "No NI” (results not shown).
• sCD127 is an immunological marker useful for determining the susceptibility of a patient to nosocomial infections, and in particular patients hospitalized in intensive care and / or who have undergone aggression (surgery, burns, trauma ...) generating a systemic inflammatory response (SIRS), and in particular patients in septic state, particularly severe, and preferably patients in septic shock.
• SIRS systemic inflammatory response

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Chemical & Material Sciences (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Urology & Nephrology (AREA)
• Physics & Mathematics (AREA)
• General Health & Medical Sciences (AREA)
• Pathology (AREA)
• Medicinal Chemistry (AREA)
• Microbiology (AREA)
• Cell Biology (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• General Physics & Mathematics (AREA)
• Food Science & Technology (AREA)
• Mechanical Engineering (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Composite Materials (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Textile Engineering (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Robotics (AREA)
• Thermal Sciences (AREA)
• Heart & Thoracic Surgery (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Surgery (AREA)
• Medical Informatics (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Materials Engineering (AREA)
• Peptides Or Proteins (AREA)
• Manufacturing & Machinery (AREA)
• Polymers & Plastics (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=48237069

Family Applications (1)

Country Status (9)

Cited By (5)

Families Citing this family (3)

Citations (2)

Family Cites Families (10)

• 2012
  • 2012-03-23 FR FR1252641A patent/FR2988479B1/fr active Active
• 2013
  • 2013-03-22 BR BR112014023387-0A patent/BR112014023387B1/pt not_active IP Right Cessation
  • 2013-03-22 EP EP13719912.1A patent/EP2828657B9/fr active Active
  • 2013-03-22 WO PCT/FR2013/050624 patent/WO2013140103A1/fr not_active Ceased
  • 2013-03-22 ES ES13719912.1T patent/ES2573807T3/es active Active
  • 2013-03-22 CN CN201380016796.3A patent/CN104246499B/zh not_active Expired - Fee Related
  • 2013-03-22 JP JP2015500971A patent/JP6162788B2/ja not_active Expired - Fee Related
  • 2013-03-22 US US14/387,076 patent/US9823239B2/en not_active Expired - Fee Related
  • 2013-03-22 AU AU2013237275A patent/AU2013237275B2/en not_active Ceased
• 2017
  • 2017-06-15 JP JP2017117517A patent/JP6458087B2/ja not_active Expired - Fee Related
  • 2017-10-18 US US15/786,755 patent/US10725029B2/en active Active

Patent Citations (2)

Non-Patent Citations (11)

Also Published As

Similar Documents

Legal Events